Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-184 in Advanced or Metastatic Solid Tumors
NCT05933265Phase 2Active, not recruiting
- Sponsor
- Lantern Pharma
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of LP-184 in solid tumor, glioblastoma (GBM), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), sponsored by Lantern Pharma. Started Jun 2023; status: active, not recruiting.
02
Drugs
LP-184
03
Conditions
solid tumorglioblastoma (GBM)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05933265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933265.